Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 2, 2012, Pages 117-123

  Nanjwade, Basavaraj K ^a   Deshmukh, Rucha V ^a   Gaikwad, Kishori R ^a   Parikh, Kemy A ^a   Manvi, F V ^a  

^a K L E S S COLLEGE OF PHARMACY   (India)

Author keywords

In situ forming systems; Moxifloxacin hydrochloride; Ophthalmic hydrogel; Poloxamer; Polyox; Sodium alginate

Indexed keywords

ALGINIC ACID; GELLING AGENT; HYDROXYPROPYLMETHYLCELLULOSE; MOXIFLOXACIN; POLOXAMER; POLYOX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; EYE; EYE IRRITATION; GELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICRO HYDROGEL; NONHUMAN; PH; RABBIT; SHEAR STRESS; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY;

ADMINISTRATION, OPHTHALMIC; ALGINATES; ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; GLUCURONIC ACID; HEXURONIC ACIDS; HYDROGELS; HYDROGEN-ION CONCENTRATION; MALE; METHYLCELLULOSE; PHASE TRANSITION; POLOXAMER; POLYETHYLENE GLYCOLS; QUINOLINES; RABBITS; TEMPERATURE; TIME FACTORS; VISCOSITY;

EID: 84863682818     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0070-9     Document Type: Article

References (16)

1. Blondeau JM (2004) Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv Ophthalmol 49:S73-S78
2. Cohen S, Lobel E, Trevgoda A, Peled Y (1997) A novel in situ forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 44:201-208
3. Jain GK, Jain N, Pathan SA, Akhter S, Talegaonkar S, Chander P, Khar RK, Ahmad FJ (2010) Ultra high-pressure liquid chromatographic assay of moxifloxacin in rabbit aqueous humor after topical instillation of moxifloxacin nanoparticles. J Pharm Biomed Anal 52:110-113
4. Jarvinen K, Tomi J, Urttia SA (1995) Ocular absorption following topical delivery. Adv Drug Deliv Rev 16:3-19
5. Jeong B, Kim SW, Bae YH (2002) Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 54:37-51
6. Liu Z, Li J, Nie S, Liu H, Ding P, Pan W (2006) Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 315:12-17
7. Manjappa AS, Nanjawade BK, Manvi FV, Murthy SR (2009) Sustained ophthalmic in situ gel of ketorolac tromethamine: Rheology and in vivo studies. Drug Deliv Res 69:1-8
8. Mansour M, Mansour S, Mortada ND (2008) Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm 34:744-752
9. Martinez M, McDermott P, Walker R (2006) Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals. Vet J 172:10-28
10. Meqi SA, Deshpande SG (2002) Ocular drug delivery: Controlled and novel drug delivery. CBS Publishers, New Delhi, pp 82-84
11. Nanjwade BK, Manvi FV, Manjappa AS (2007) In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 122:119-134
12. Olejnik O (1993) Conventional systems in ophthalmic drug delivery. In: Mitra AK (ed) Ophthalmic drug delivery systems. Marcel Dekker, New York, pp 179-193
13. Sasaki H, Yamamura K, Nishida K, Nakamurat J, Ichikawa M (1996) Delivery of drugs to the eye by topical application. Prog Retin Eye Res 15:553-620
14. Silver LH, Woodside AM, Montgomery DB (2005) Clinical safety of moxifloxacin ophthalmic solution 0.5% (vigamox) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol 50:S55-S63
15. Srividya B, Cardoza RM, Amin PD (2001) Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 73:205-211
16. Netland PA (2007) Glaucoma medical therapy, principles and management. 2nd Ophthalmic Monograph 13:11-14